For how we live.
In 422 people with active lupus in the BILAG-BR cohort, fewer than a quarter met major response at 12 months. Black patients had about an eighth the adjusted odds of response of White patients.
In a 98-patient French trial, six-monthly rituximab did not extend remission beyond daily azathioprine in this rare eosinophilic vasculitis — and recipients had more severe infections.
LOTIS-9 tested loncastuximab tesirine plus rituximab in unfit and frail older adults with untreated DLBCL. Complete responses reached 53% and 42%, but severe side effects, including 11 deaths, ended the trial early.
A single-arm phase 2 trial added glofitamab to pola-R-CHP in 41 people with newly diagnosed B-cell lymphoma. The best complete-response rate was 95%, cytokine release stayed grade 1, and no neurotoxicity was reported.
The academic MATRix/IELSG43 trial found autologous transplant lifted 3-year progression-free survival to 78% from 51%, but at the cost of more toxicity and more treatment-related deaths.
In the single-arm EPCORE NHL-2 cohort, adding epcoritamab to rituximab and lenalidomide produced responses in 95% of 41 untreated follicular lymphoma patients, with no control group to prove added benefit.
In the phase 3 BRUIN CLL-322 trial, adding pirtobrutinib to a fixed course of venetoclax and rituximab raised 24-month progression-free survival to 87% from 72% in previously treated disease.
In the head-to-head OVERLORD-MS trial, 92.2% on rituximab and 94.8% on ocrelizumab had no new MRI lesions from months 6 to 24, meeting the prespecified bar for noninferiority.